Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

INREBIC® (Fedratinib)

August 17, 2019April 5, 2020 RR FDA Approvals
Myelofibrosis

The FDA on August 16, 2019 approved INREBICĀ® for adults with intermediate-2 or high-risk Primary or Secondary (post-Polycythemia Vera or post-Essential Thrombocythemia) Myelofibrosis (MF). INREBICĀ® is a product of Impact Biomedicines, Inc.

Related Posts:

  • FDA Approves INREBIC® for Myelofibrosis

Post navigation

ROZLYTREK® (Entrectinib)
FDA Approves ROZLYTREK® for NTRK Positive tumors and ROS1 Positive Non Small Cell Lung Cancer

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

oncoprescribe-ad

Advertisement

Ad 2

OncoPrescribe

Advertisement

Ad 3

OncoPrescribe.com-Ad

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved